- Home
- LYEL vs ZNTL Comparison
LYEL vs ZNTL Comparison
Compare LYEL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | ZNTL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 468.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LYEL | ZNTL |
|---|---|---|
| Price | $23.86 | $5.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $30.60 | $6.60 |
| AVG Volume (30 Days) | 76.6K | ★ 3.7M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,285.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $1.13 |
| 52 Week High | $45.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | LYEL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 69.82 |
| Support Level | $21.27 | $1.31 |
| Resistance Level | $27.30 | N/A |
| Average True Range (ATR) | 1.70 | 0.67 |
| MACD | 0.50 | 0.35 |
| Stochastic Oscillator | 80.58 | 71.41 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.